Aidea Pharma(SH:688488) Zheng Quan Zhi Xing·2025-06-27 16:50Core Viewpoint - The legal opinion letter from Shanghai Chengming Zhenzheng Law Firm confirms the validity of the cancellation of unvested restricted stock under Jiangsu Aidi Pharmaceutical Co., Ltd.'s 2022 incentive plan, stating that necessary approvals and authorizations have been obtained and that the actions comply with relevant laws and regulations [1][9]. Summary by Sections Approval and Authorization of Stock Cancellation - The company has obtained necessary approvals for the cancellation of unvested restricted stock as per the 2022 incentive plan, including resolutions from various meetings and independent directors' opinions [5][6][9]. Details of Canceled Restricted Stock - A total of 500,501.6 shares of restricted stock have been canceled due to various reasons: - 252,450 shares were canceled because 36 initial grantees and 13 reserved grantees left the company [6][9]. - 231,060 shares were canceled due to unmet performance targets in the HIV drug business for the years 2022, 2023, and 2024 [7][8][9]. - 16,650 shares were canceled as 10 reserved grantees voluntarily forfeited their rights [8][9]. - 3,416 shares were canceled because one initial grantee failed to pay the subscription fee [8][9]. Compliance with Regulations - The cancellation of restricted stock aligns with the provisions of the Company Law, Securities Law, and relevant management regulations, confirming that the actions taken are legally compliant [9].